CGON · CG Oncology Inc
Price
Snapshot
50 fields · last close| Market Cap | $6.61B |
| P/E | — |
| Float | 83.83M |
| Beta | 0.21 |
| Volatility | 5.3% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 70 |
| Price | 76.40 |
| Change | +2.39% |
| Prev Close | 74.62 |
| Open | 75.87 |
| Day Low | 72.82 |
| Day High | 75.87 |
| Avg Vol | 1 |
| Avg $ Vol | $61.90M |
| 52W High | 80.97 |
| 52W Low | 35.64 |
| 52W Pos | 89.9% |
| From High | −5.64% |
| From Low | +114.37% |
| Max DD 1Y | −27.41% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.61% |
| SMA 50 | +3.14% |
| SMA 200 | +22.34% |
| RSI (14) | 50.7 |
| Vol 30D | 35.9% |
| Vol 90D | 49.0% |
| 1Y Range | 36–81 |
| Daily bars | 516 |
| Perf Week | +3.14% |
| Perf Month | −7.51% |
| Perf Quarter | +22.17% |
| Perf Half Y | +13.30% |
| Perf Year | +97.83% |
| Perf YTD | +82.82% |
| Prev Day | +2.39% |
| Clavix | B- |
| Debt / Eq | 0.00 |
| Curr Ratio | 24.63 |
| Int Cover | -35,442.0× |
| FCF Margin | — |
| Rev Growth | +176.6% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 19 / 35 |
Clavix risk grade
regraded every trading dayCGON grades B-, 70 of 100. Steadiest on Macro Resilience (64), most exposed on Price Stability (52, mixed). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 19 of 35 in Biotechnology by Clavix score.
How rough the ride is
| CGON | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.21 | 0.51 |
| Volatilityannualized | 5.3% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −27.4% | — |
| Typical daily movemedian absolute daily change | 2.07% | — |
| Days beyond ±3%of the last 252 sessions | 8032% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CGON | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.21 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CGON | |
|---|---|
| 1 week | +3.1% |
| 1 month | −7.5% |
| Year to date | +82.8% |
| 1 year | +97.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CGON | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 20since 25 Jun |
| Average score0 most bearish, 100 most bullish | 50 |
| Bullish · bearisharticles above 60 · below 40 | 10 · 9 |
| Directionarticles whose tone is improving vs worsening | 10 ↑ 9 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| CGON | |
|---|---|
| Revenue growthyear over year | +176.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openBank of America disclosed in an SEC filing that it bought a new stake in CG Oncology during the second quarter, purchasing 984,918 shares worth about $70 million. The article does not include any further details about CG Oncology's business.
CG Oncology director Leonard Post sold 1,000 shares on September 15th at an average price of $72.98, totaling about $72,980. After the sale he still holds 1,000 shares, which means his direct stake in the company was cut in half.
CG Oncology (CGON) shares are up 160.2% over the past year. A valuation check in the article argues the stock now looks fully priced, with much of the pipeline-to-revenue story already reflected in the share price.
CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, reporting a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C with no Grade 3+ adverse events. A rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
CG Oncology reported quarterly EPS of ($0.90), missing analyst consensus estimates of ($0.66) by $0.24, alongside a negative net margin of 3,602.68% and a negative return on equity of 26.58%.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| IONS | Ionis Pharmaceuticals Inc | B- | $7.39B | — | 0.41 | Compare |
| PTCT | PTC Therapeutics Inc | B | $5.46B | 7.99 | 0.50 | Compare |
| ERAS | Erasca Inc | C | $5.17B | — | 0.71 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.47B | 80.58 | 0.39 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.71B | 19.72 | 1.90 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $9.25B | 111.61 | 1.18 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $9.39B | — | 1.33 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.